EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial

Ángel Guerrero-Zotano, Miguel Gil-Gil, Amy Williams, Manuel Ruiz-Borrego, Hanna Ritzén, Eva María Ciruelos, Montserrat Muñoz, Begoña Bermejo, Mireia Margelí, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi und 15 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116817 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Ángel Guerrero-Zotano und 26 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Valenciano de Oncología (IVO), Valencia, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain. Electronic address: angel.guerrero.zotan…. Hauptthemen laut MEDLINE: Breast Neoplasms, Thymidine Kinase, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc, AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsThymidine KinaseAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmBiomarkers, TumorHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesPyridinesAgedPiperazinesCapecitabineReceptors, EstrogenReceptors, ProgesteroneAdultAntineoplastic Agents, HormonalProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

BiomarkerCapecitabineEndocrine resistanceHR+ /HER2 − metastatic breast cancerPalbociclibThymidine kinase 1 (TK1)Treatment response monitoring

Substanzen

Thymidine KinaseErb-b2 Receptor Tyrosine KinasesPyridinespalbociclibPiperazinesCapecitabinethymidine kinase 1Biomarkers, TumorReceptors, EstrogenERBB2 protein, human

Autor:innen und Institutionen

  • Instituto Valenciano de Oncología (IVO), Valencia, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain. Electronic address: angel.guerrero.zotano@gmail.com.
  • GEICAM Spanish Breast Cancer Group, Madrid, Spain; Institut Català d'Oncologia (ICO) & IDIBELL, Servicio de Oncología Médica. L'Hospitalet. Barcelona, Spain.
  • Biovica International AB, Sweden.
  • GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • GEICAM Spanish Breast Cancer Group, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Servicio Oncología Médica, Madrid, Spain; Medical Oncology, HM Hospitales, Madrid, Spain; SOLTI Gr…
  • GEICAM Spanish Breast Cancer Group, Madrid, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumours, August Pi I Sunyer Biomedical Resea…

Förderung

  • Pfizer Inc
  • AstraZeneca PLC

Zitieren

APA

Guerrero-Zotano, Á., Gil-Gil, M., Williams, A., Ruiz-Borrego, M., Ritzén, H., Ciruelos, E. M., Muñoz, M., Bermejo, B., Margelí, M., Antón, A., Kahan, Z., Csöszi, T., Murillo, L., Murillo, S. M., Lang, I., Rendo, C. R., Alba, E., Álvarez, P., de la Haba-Rodriguez, J., …, & Martín, M. (2026). Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116817

Vancouver

Guerrero-Zotano Á, Gil-Gil M, Williams A, Ruiz-Borrego M, Ritzén H, Ciruelos EM, et al. Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116817

BibTeX
@article{GuerreroZotano2026,
  author = {Guerrero-Zotano, Ángel and Gil-Gil, Miguel and Williams, Amy and Ruiz-Borrego, Manuel and Ritzén, Hanna and Ciruelos, Eva María and Muñoz, Montserrat and Bermejo, Begoña and Margelí, Mireia and Antón, Antonio and Kahan, Zsuzsanna and Csöszi, Tibor and Murillo, Laura and Murillo, Serafín Morales and Lang, Istvan and Rendo, Cristina Reboredo and Alba, Emilio and Álvarez, Pablo and de la Haba-Rodriguez, Juan and Álvarez, Isabel and García, Andrés and Herranz, Jesús and Caballero, Rosalía and Fisker, Helle and Portela, Marta and Rojo, Federico and Martín, Miguel},
  title = {Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116817}
}
Kostenlos starten →